Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Top 20 neurology products in the U.S. based on revenue in 2016 (in million U.S. dollars)*

Exclusive Premium Statistic

Revenue of top 20 neurology products in the U.S. 2016 This statistic displays the projected top 20 products for neurology diseases based on revenue in the United States during 2016. In that year, Abilify, an Otsuka product, is expected to generate approximately 322 million U.S. dollars in revenues, a decrease of some 1.7 billion dollars compared to 2014, caused by patent loss.
Show more
Product name (company)Revenue in million U.S. dollars
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
Product name (company)Revenue in million U.S. dollars
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1.5m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account


only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

View price details

Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1.5m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account


only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

View price details

Download Settings Share
Chart type
Datalabels
Share on Social Media
Download started
Please be patient - this may take a moment
Description Source More information
This statistic displays the projected top 20 products for neurology diseases based on revenue in the United States during 2016. In that year, Abilify, an Otsuka product, is expected to generate approximately 322 million U.S. dollars in revenues, a decrease of some 1.7 billion dollars compared to 2014, caused by patent loss.
Show more
Release date
October 2016
Region
United States
Survey time period
as of October 2016
Supplementary notes
* All values are projected. The original list inlcudes products FDA indicates as approved for treatimg MS, Parkinson's disease, Alzheimer's disease, depression, schizophrenia, bipolar and insomnia.
Open this statistic in...

More information

Statista Accounts: Access All Statistics. Starting from $588 / Year

Basic Account

Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account

Your perfect start with Statista

  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account

Full access

Corporate solution including all features.

Send request

* All products require an annual contract.
   Prices do not include sales tax
   (New York residents only).
Leading companies trust Statista:

Related Studies: Available to Download in PDF or PPTX Format

Pharmaceutical brands: Abilify (BMS/Otsuka)

All Information
in one Presentation

Pharmaceutical brands: Abilify (BMS/Otsuka)

Everything On "Pharmaceutical brands: Abilify (BMS/Otsuka)" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Other Reports & Dossiers
Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Pharmaceutical brands: Abilify (BMS/Otsuka)"

  • Overview
  • Drug prices and consumer behavior
  • Advertising expenditures
Need help with using Statista for your research? Tutorials and first steps

Further Content: Statistics, Studies, and Topic Pages

Statistics on the topic

Topics

About Statista

Learn more about how Statista can support your business.

Request webinar
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.

News